Special Issue "HDAC Inhibitors"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 July 2011)

Special Issue Editor

Guest Editor
Prof. Dr. H. Miles Prince
Centre for Blood Cell Therapies, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A\'Beckett St Melbourne 8006, Victoria, Australia
E-Mail: miles.prince@petermac.org
Interests: blood clotting; bleeding disorders; transfusion medics; myeloma therapy (clinical and pre-clinial)and biology; cutaneous T cell lymphoma (clinical); immunotherapy; epigenetics

Special Issue Information

Dear Colleagues,

Histone deacetylase inhibitors are clearly effective therapeutic tools in the treatment of cancers, particularly haematological malignancies. The purpose of this special issue is to provide the reader with a focused review of on the current place of HDACi as a therapy, particularly in blood cancers. We hope to provide a broad overview of the rationale behind their use, with specific papers focusing on diseases where they clearly have biological effects - NHL, Hodgkin disease, myeloid malignancies. Finally we hope to have two seperate papers examining mechanisms of resistance and common toxicities.

I hope you will be able to contribute to what I see will be a valuable compendium of insightful reviews in this very topical subject.

Prof. Dr. H. Miles Prince
Guest Editors

Keywords

  • histone deacetylase
  • epigenetics
  • demethylation
  • novel therapies
  • transcription factors

Published Papers (5 papers)

Pharmaceuticals 2011, 4(12), 1578-1590; doi:10.3390/ph4121578
Received: 18 October 2011; in revised form: 30 November 2011 / Accepted: 30 November 2011 / Published: 14 December 2011
Show/Hide Abstract | Download PDF Full-text (368 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2011, 4(8), 1183-1195; doi:10.3390/ph4081183
Received: 25 July 2011; in revised form: 11 August 2011 / Accepted: 15 August 2011 / Published: 22 August 2011
Show/Hide Abstract | Download PDF Full-text (571 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2010, 3(9), 2751-2767; doi:10.3390/ph3092751
Received: 23 June 2010; in revised form: 18 August 2010 / Accepted: 19 August 2010 / Published: 26 August 2010
Show/Hide Abstract | Download PDF Full-text (130 KB)

Pharmaceuticals 2010, 3(8), 2674-2688; doi:10.3390/ph3082674
Received: 23 July 2010; in revised form: 12 August 2010 / Accepted: 13 August 2010 / Published: 17 August 2010
Show/Hide Abstract | Download PDF Full-text (163 KB)

Pharmaceuticals 2010, 3(8), 2441-2469; doi:10.3390/ph3082441
Received: 16 July 2010; in revised form: 30 July 2010 / Accepted: 2 August 2010 / Published: 4 August 2010
Show/Hide Abstract | Download PDF Full-text (413 KB)

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert